Biocorrx (OTCMKTS:BICX) Issues Earnings Results, Beats Estimates By $0.11 EPS

Biocorrx (OTCMKTS:BICX) released its quarterly earnings results on Tuesday. The company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.11, Zacks reports. The firm had revenue of ($0.15) million during the quarter, compared to analyst estimates of $0.22 million.

Biocorrx Price Performance

BICX stock remained flat at $0.40 during midday trading on Wednesday. 200 shares of the company’s stock traded hands, compared to its average volume of 1,219. The firm has a market cap of $10.56 million, a PE ratio of -1.25 and a beta of 0.33. The business has a fifty day moving average price of $0.35 and a two-hundred day moving average price of $0.36. Biocorrx has a 12-month low of $0.20 and a 12-month high of $0.50.

Biocorrx Company Profile

BioCorRx Inc, through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. It distributes and licenses BioCorRx recovery program, a non-addictive and medication-assisted treatment program that includes a counseling program coupled with its proprietary naltrexone implant; and distributes UnCraveRx weight loss management program, a medically assisted weight management program to reduce food cravings combined with on-demand virtual lifestyle support, fitness, and nutrition.